MedTrace Logo

Optimizing Y90 Therapy for Radiation Lobectomy

NCT04390724 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2026-03-27

No results posted yet for this study

Summary

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Conditions

Interventions

DEVICE

Y90 radioembolization

Patients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant

Sponsors & Collaborators

Principal Investigators

  • Robert Lewandowski, MD · Northwestern University

  • Jeremy Collins, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04390724 on ClinicalTrials.gov